Skip to Content
Find out what’s happening at AAO2016. Visit ConferenceInsider here >>

Lidocaine (Ophthalmic)



(LYE doe kane)

Index Terms

  • Lidocaine Hydrochloride
  • Lignocaine Hydrochloride

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Gel, Ophthalmic [preservative free]:

Akten: 3.5% (1 mL)

Gel, Ophthalmic, as hydrochloride [preservative free]:

Akten: 3.5% (5 mL [DSC])

Brand Names: U.S.

  • Akten

Pharmacologic Category

  • Local Anesthetic
  • Local Anesthetic, Ophthalmic


Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.

Onset of Action

20 seconds to 5 minutes (median: 40 seconds)

Duration of Action

5-30 minutes (median: 15 minutes)

Use: Labeled Indications

To provide local anesthesia to ocular surface during ophthalmologic procedures


There are no contraindications listed in the manufacturer’s labeling

Dosing: Adult

Anesthesia, ocular: Apply 2 drops to ocular surface in area where procedure will occur; may reapply to maintain effect.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Anesthesia, ocular: Refer to adult dosing


Store at 15°C to 25°C (59°F to 77°F). Protect from light. Discard after use.

Drug Interactions

There are no known significant interactions.

Adverse Reactions

Frequency not defined.

Central Nervous System: Localized burning

Ophthalmic: Conjunctival hyperemia, diplopia, epithelial keratopathy, visual disturbance


Concerns related to adverse effects:

• Corneal ulceration: Prolonged use may cause permanent corneal ulceration and/or opacification with loss of vision.

Dosage form specific issues:

• Appropriate use: For ophthalmic use only; not for injection.

Pregnancy Risk Factor


Pregnancy Considerations

Adverse events were not observed in animal reproduction studies. Although systemic exposure is not expected following application of the ophthalmic gel, cumulative exposure from all routes of administration should be considered.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience burning or headache. Have patient report immediately to prescriber vision changes, eye pain, severe eye irritation, eye discharge, or blindness (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.

More about lidocaine ophthalmic

Consumer resources

Professional resources

Related treatment guides